Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIV-2X Darwin influenza vaccine
- Development stage
- Phase 1
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TIV-2X Darwin influenza vaccine is an influenza vaccine formulation developed by Sanofi Pasteur. It is composed of the World Health Organization (WHO)-recommended virus strains along with an additional H3 strain. The vaccine is designed to evaluate its safety and immunogenicity in healthy adult participants. It is administered intramuscularly.
- Other names
- TIV-2X DarwinTIV2X DarwinTIV 2X Darwin
02
Targets
Sia-glycan (Host sialylated glycan receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on TIV-2X Darwin influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIV-2X Darwin influenza vaccine.